Image Description

INVESTORS
& MEDIA

circle

INVESTOR OVERVIEW

  • Webcast Image Webcast
    X Q2 2017 Cytokinetics, Inc. Earnings Conference Call
    Aug 2, 2017 at 4:30 PM EDT

    Q2 2017 Cytokinetics, Inc. Earnings Conference Call
    Aug 2, 2017 at 4:30 PM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

03/15/17
( FY )
ALS

ALS

03/15/17
( FY )
SMA

SMA

03/15/17
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics to Release Fourth Quarter and Full Year 2005 Results on January 31, 2006
Cytokinetics to Release Fourth Quarter and Full Year 2005 Results on January 31, 2006 South San Francisco, CA, January 24, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it will report fourth quarter and year end 2005 financial results on Tuesday, January 31, 2006 at 4:00
Toggle Summary Additional Phase I Clinical Trial Data Related to Omecamtiv Mecarbil to Be Presented at the 2010 Heart Failure Society of America Annual Meeting
SOUTH SAN FRANCISCO, CA, Sep 08, 2010 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that additional Phase I clinical trial data relating to omecamtiv mecarbil (formerly CK-1827452) is scheduled to be presented as a poster presentation at the 2010 Heart Failure
Toggle Summary Amgen and Cytokinetics Announce Expansion of License for Omecamtiv Mecarbil
Cytokinetics Will Receive $25 Million Plus Potential Milestone Payments and Royalties THOUSAND OAKS, Calif. AND SOUTH SAN FRANCISCO, Calif, (June 12, 2013) - Amgen (NASDAQ:AMGN) and Cytokinetics Incorporated (NASDAQ:CYTK) today announced an expansion of their strategic collaboration to include
Toggle Summary Amgen and Cytokinetics Announce Late-Breaking Presentation of COSMIC-HF Trial at AHA Scientific Sessions 2015
First Chronic Dosing Trial of Oral Omecamtiv Mecarbil Showed Statistically Significant Improvements in Several Pre-Specified Measures of Cardiac Function and Volumes THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 08, 2015 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Cytokinetics

EVENTS

There are currently no events to display.